Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 13 (Search time: 0.113 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2017Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trialGuimarães, P.; Wojdyla, D.; Alexander, J.; Thomas, L.; Alings, M.; Flaker, G.; Al-Khatib, S.; Hanna, M.; Horowitz, J.; Wallentin, L.; Granger, C.; Lopes, R.
2013N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: Insights from the aristotle trial (apixaban for the prevention of stroke in subjects with atrial fibrillation)Hijazi, Z.; Wallentin, L.; Siegbahn, A.; Andersson, U.; Christersson, C.; Ezekowitz, J.; Gersh, B.; Hanna, M.; Hohnloser, S.; Horowitz, J.; Huber, K.; Hylek, E.; Lopes, R.; McMurray, J.; Granger, C.
2014High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarinHijazi, Z.; Wallentin, L.; Siegbahn, A.; Andersson, U.; Alexander, J.; Atar, D.; Gersh, B.; Hanna, M.; Harjola, V.; Horowitz, J.; Husted, S.; Hylek, E.; Lopes, R.; McMurray, J.; Granger, C.
2010Apixaban for reduction in stroke and other ThromboemboLic events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationaleLopes, R.; Alexander, J.; Al-Khatib, S.; Ansell, J.; Diaz, R.; Easton, J.; Gersh, B.; Granger, C.; Hanna, M.; Horowitz, J.; Hylek, E.; McMurray, J.; Verheugt, F.; Wallentin, L.
2014Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trialWallentin, L.; Hijazi, Z.; Andersson, U.; Alexander, J.; De Caterina, R.; Hanna, M.; Horowitz, J.; Hylek, E.; Lopes, R.; Åsberg, S.; Granger, C.; Siegbahn, A.
2015Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudyHijazi, Z.; Siegbahn, A.; Andersson, U.; Lindahl, B.; Granger, C.; Alexander, J.; Atar, D.; Gersh, B.; Hanna, M.; Harjola, V.; Horowitz, J.; Husted, S.; Hylek, E.; Lopes, R.; McMurray, J.; Wallentin, L.
2014High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: Insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trialHijazi, Z.; Siegbahn, A.; Andersson, U.; Granger, C.; Alexander, J.; Atar, D.; Gersh, B.; Mohan, P.; Harjola, V.; Horowitz, J.; Husted, S.; Hylek, E.; Lopes, R.; McMurray, J.; Wallentin, L.
2016History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trialDe Caterina, R.; Andersson, U.; Alexander, J.; Al-Khatib, S.; Bahit, M.; Goto, S.; Hanna, M.; Held, C.; Hohnloser, S.; Hylek, E.; Lanas, F.; Lopes, R.; López-Sendón, J.; Renda, G.; Horowitz, J.; Granger, C.; Wallentin, L.
2014Response to letter regarding article, "efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation"Wallentin, L.; Lopes, R.; Hanna, M.; Thomas, L.; Hellkamp, A.; Nepal, S.; Hylek, E.; Al-Khatib, S.; Alexander, J.; Alings, M.; Amerena, J.; Ansell, J.; Aylward, P.; Bartunek, J.; Commerford, P.; De Caterina, R.; Erol, C.; Harjola, V.; Held, C.; Horowitz, J.; et al.
2014D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trialChristersson, C.; Wallentin, L.; Andersson, U.; Alexander, J.; Ansell, J.; De Caterina, R.; Gersh, B.; Granger, C.; Hanna, M.; Horowitz, J.; Huber, K.; Husted, S.; Hylek, E.; Lopes, R.; Siegbahn, A.